Docetaxel News and Research

RSS

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

6 Jun 2016

Oncologists to present latest research findings at ASCO annual meeting

Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology annual meeting, June 3-7 in Chicago.

28 May 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.

20 Apr 2016

Value of PD-L1 testing in NSCLC debated

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 expression in patients with non-small-cell lung cancer treated with checkpoint inhibitors.

18 Mar 2016

Experimental drug improves survival rate of majority of lung cancer patients compared to standard chemotherapy

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

15 Mar 2016

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis.

11 Mar 2016

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival.

16 Feb 2016

ASTRO's new research journal 'Advances in Radiation Oncology' closes first issue

Advances in Radiation Oncology, ASTRO's new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy.

12 Feb 2016

NICE recommends Xofigo (radium-223 dichloride) for prostate cancer patients after treatment with docetaxel

The National Institute for Health and Care Excellence has issued its final guidance recommending Xofigo for use on the NHS in England and Wales as an option for treating adult men, with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

4 Feb 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.

11 Jan 2016

FDA approves non-alcoholic Docetaxel Injection

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

29 Dec 2015

Study shows more patients with advanced NSCLC may benefit from pembrolizumab

More patients with advanced non-small-cell lung cancer (NSCLC) could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore), in conjunction with a publication in The Lancet.

22 Dec 2015

Immunotherapy more effective than chemotherapy in treating patients with advanced lung cancer

A new study has found immunotherapy to be more effective than chemotherapy in treating most previously treated patients with advanced lung cancer, and demonstrated effectiveness in a wider population of people than previously known to benefit from the therapy.

22 Dec 2015

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Metastasis - or the spread of cancer from one part of the body to other parts - accounts for more than 90 percent of cancer-related deaths. Although the cells that seed metastasis and the sites that they tend to travel to have been increasingly studied over the years, little has been known about how cancer migrates from a primary site, such as breast tissue, to a secondary site, such as the brain or bone marrow.

16 Dec 2015

NICE recommends Xofigo (radium-223 dichloride) for patients with advanced prostate cancer

The National Institute for Health and Care Excellence today issued its Final Appraisal Determination (FAD) recommending Xofigo (radium-223 dichloride) for use on the NHS in England as an option for treating adult men, with hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, who have received previous docetaxel therapy.

20 Nov 2015

Prostate cancer market to expand at CAGR of 9.5% to $13.6 billion by 2021

Analysis from business intelligence provider GBI Research - Prostate Cancer Market to 2021 - Increasing Disease Prevalence to be a Key Driver of Market Growth - says that the prostate cancer market will expand at a rapid Compound Annual Growth Rate (CAGR) of 9.5% from $7.6 billion in 2014 to $13.6 billion by 2021.

12 Nov 2015

Entry of eleven novel therapies expected to drive NSCLC market's growth to $12.7 billion in 2024

Decision Resources Group finds that the entry of eleven novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.4 billion in 2014 to $12.7 billion in 2024.

27 Oct 2015

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.

23 Oct 2015